The Phase I trial of ADC CX-2051 in colorectal cancer will continue, based on a decision made by a safety committee.

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease ...

Among 41 patients with this rare and highly aggressive RCC subtype, the objective response rate (ORR) was 56% with the ...

Pfizer (PFE) announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 ...